Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
NCT06599619
·
clinicaltrials.gov ↗
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
Single agent, adjuvant anti-PD1 therapy
Sponsor
John Kirkwood
Collaborators
[object Object]
[object Object]